-
Exenatide is an incretin mimetic that is similar to the glucagon-like peptide-1(GLP-1) in the body, and acts by binding to GLP-1 receptors. It improves glycemic control by increasing glucose-dependent insulin secretion, improving first-phase insulin response, decreasing glucagon secretion, slowing gastric emptying, and reducing food intake.
-
-
Medication reconciliation is a requirement of the Joint Commission on Accreditation of Healthcare Organizations in Oakbrook Terrace, IL. Many hospitals, however, still are bogged down in details of developing and implementing this process. A Joint Commission surveyor recently gave some tips on navigating the rough waters.
-
The last important piece of the medication reconciliation process is for hospitals to provide a list of the patients current (continuing) medications for his or her next level of care.
-
Viventia Biotech has announced that the FDA has designated the companys lead drug, Proxinium (formerly known as VB4-845), as a fast-track product for the treatment of patients with recurrent squamous cell carcinoma of the head and neck.
-
It's been more than six years since the Office of Inspector General (OIG) published its compliance program guidance for hospices, listing 28 areas in which hospices are particularly vulnerable to fraud and abuse.
-
A new job can be overwhelming no matter what industry you may choose, but when the new job is in home care, saying that the job is overwhelming may be an understatement.
-
-
Despite national and various regional focuses on improving minority access to hospice, many challenges remain, hospice diversity experts say.
-
National Hospice & Palliative Care Organization (NHPCO) of Alexandria, VA, is developing a diversity toolkit to assist hospices with their efforts to diversify their patient population.
